Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Early histomorphometric changes in response to parathyroid hormone therapy in osteoporosis: evidence for de novo bone formation on quiescent cancellous surfaces.

× No keyword cloud information.

16 in total

Review 1. Stemming bone loss by suppressing apoptosis.

Authors: J M Hock
Journal: J Clin Invest Date: 1999-08 Impact factor: 14.808

Review 2. Regulatory pathways revealing new approaches to the development of anabolic drugs for osteoporosis.

Authors: T J Martin; N A Sims; K W Ng
Journal: Osteoporos Int Date: 2008-03-13 Impact factor: 4.507

Review 3. Parathyroid hormone for the treatment of osteoporosis: a systematic review.

Authors: Ann Cranney; Alexandra Papaioannou; Nicole Zytaruk; David Hanley; Jonathan Adachi; David Goltzman; Timothy Murray; Anthony Hodsman
Journal: CMAJ Date: 2006-07-04 Impact factor: 8.262

4. Parathyroid hormone plus alendronate in osteoporosis: a meta-analysis of randomized controlled trials.

Authors: Qinggang Zhang; Jing Qian; Yuchang Zhu
Journal: Int J Clin Exp Med Date: 2015-03-15

Review 5. The bone-building action of the parathyroid hormone: implications for the treatment of osteoporosis.

Authors: J F Whitfield; P Morley; G E Willick
Journal: Drugs Aging Date: 1999-08 Impact factor: 3.923

6. Intermittent Parathyroid Hormone After Prolonged Alendronate Treatment Induces Substantial New Bone Formation and Increases Bone Tissue Heterogeneity in Ovariectomized Rats.

Authors: Allison R Altman-Singles; Yonghoon Jeong; Wei-Ju Tseng; Chantal Mj de Bakker; Hongbo Zhao; Carina Lott; Juhanna Robberts; Ling Qin; Lin Han; Do-Gyoon Kim; X Sherry Liu
Journal: J Bone Miner Res Date: 2017-06-13 Impact factor: 6.741

7. The small GTPase RhoA is crucial for MC3T3-E1 osteoblastic cell survival.

Authors: Tomohiko Yoshida; Mary F Clark; Paula H Stern
Journal: J Cell Biochem Date: 2009-04-01 Impact factor: 4.429

8. Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis.

Authors: R Lindsay; P Miller; G Pohl; E V Glass; P Chen; J H Krege
Journal: Osteoporos Int Date: 2008-10-16 Impact factor: 4.507

9. Endogenous FGF-2 is critically important in PTH anabolic effects on bone.

Authors: Maria Giovanna Sabbieti; Dimitrios Agas; Liping Xiao; Luigi Marchetti; J Douglas Coffin; Thomas Doetschman; Marja M Hurley
Journal: J Cell Physiol Date: 2009-04 Impact factor: 6.384

10. Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: a 6-month dose-response study.

Authors: Akimitsu Miyauchi; Toshio Matsumoto; Hirofumi Shigeta; Mika Tsujimoto; Daniel Thiebaud; Toshitaka Nakamura
Journal: J Bone Miner Metab Date: 2008-11-01 Impact factor: 2.626